News

Article

PTSM: Pharmaceutical Technology Sourcing and Management

PTSM: Pharmaceutical Technology Sourcing and Management

PTSM: Pharmaceutical Technology Sourcing and Management-02-01-2017
Volume12
Issue 2

Catalent to Develop Softgels for Orphan Drug Candidate

Catalent announces a development agreement with JOT to evaluate softgel options for a resveratrol drug candidate.

Catalent Pharma Solutions has announced that the company will evaluate Jupiter Orphan Therapeutics, Inc.’s novel formulation of resveratrol, JOTROL, for delivery using Catalent’s R.P. Scherer softgel technology. Under the agreement announced Jan. 9, 2017, Catalent will assess different softgel delivery technologies for JOTROL to determine the optimum oral dosage form, before manufacturing doses for human pharmacokinetics studies and Phase II clinical studies.

JOTROL, which is being developed to remedy resveratrol’s poor bioavailability and dose limiting gastrointestinal side effects, is being studied in multiple pre-clinical and clinical trial programs for the treatment of rare diseases linked to single gene deficiencies, as reported in a press statement.

Catalent will assess both conventional softgel and Catalent’s proprietary OptiShell gelatin-free technology. Catalent reports that OptiShell allows for higher fill temperatures and pH, and can accommodate semi-solid and highly viscous formulations and a wider range of excipients designed to improve bioavailability and stability.

Catalent will conduct its work on JOTROL from its St. Petersburg, FL facility, which offers formulation development and manufacturing of prescription and over-the-counter softgels, and has an annual capacity of more than 18 billion capsules a year.

Source: Catalent Pharma Solutions

 

Newsletter

Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.

Related Videos
A global supply chain map, visualizing the complex network of transportation routes and distribution centers | Image Credit: © venusvi - stock.adobe.com
Shortcut from point A to point B | Image Credit: © Olivier Le Moal - stock.adobe.com
Behind the Headlines, Episode 21: Waters-BD Merger, Merck’s $10B Bet, and Biotech’s Investment Frontiers
Wooden blocks spelling TARIFFS are placed on a map of North America, specifically over the United States and Mexico | Image Credit: © Rokas - stock.adobe.com
Jason Waite, International Trade Expert, Alston & Bird
Simona Guidi, Associate Director, ProPharma
Tore Bergsteiner
Behind the Headlines, Episode 20: CAR-T Milestones, Abbvie and Eli Lilly M&A Moves, and More
Related Content